Lacosamide
Authors:
- Emilio PeruccaEmilio Perucca
- Uma YasothanUYUma Yasothan
- Gilbert ClinckeGCGilbert Clincke
- Peter KirkpatrickPKPeter Kirkpatrick
- 1 December 2008
- journal article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 7 (12) , 973-974
Abstract
In August 2008, lacosamide (Vimpat; UCB), was granted market authorization by the European Commission as an adjunctive therapy for partial-onset seizures with or without secondary generalization in patients with epilepsy. It was approved by the FDA as an adjunctive therapy for partial-onset seizures in October 2008.Keywords
This publication has 13 references indexed in Scilit:
- The Investigational Anticonvulsant Lacosamide Selectively Enhances Slow Inactivation of Voltage-Gated Sodium ChannelsMolecular Pharmacology, 2008
- Development of new antiepileptic drugs: challenges, incentives, and recent advancesThe Lancet Neurology, 2007
- Efficacy and Safety of Oral Lacosamide as Adjunctive Therapy in Adults with Partial‐Onset SeizuresEpilepsia, 2007
- Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsyEpilepsy Research, 2007
- Lacosamide: A Review of Preclinical PropertiesCNS Drug Reviews, 2007
- EpilepsyNew England Journal of Medicine, 2003
- Evolving Treatment Strategies for EpilepsyJAMA, 2002
- Synthesis and Anticonvulsant Activities of N-Benzyl-2-acetamidopropionamide DerivativesJournal of Medicinal Chemistry, 1996
- Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation?Epilepsy Research, 1994
- Effect of Structural Modification of the Hydantoin Ring on Anticonvulsant ActivityJournal of Medicinal Chemistry, 1985